Relevant bibliographies by topics / Preclinical tumor models

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Preclinical tumor models'

Author: Grafiati
Published: 8 June 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Preclinical tumor models.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Preclinical tumor models"

1

Varticovski, L., M. G. Hollingshead, M. R. Anver, et al. "Preclinical testing using tumors from genetically engineered mouse mammary models." Journal of Clinical Oncology 24, no. 18_suppl (2006): 10067. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10067.

Full text
Abstract:
10067 Background: Mouse models have been used extensively in preclinical testing of anticancer drugs. However, few of these models reflect the progression of human disease, and even fewer predict the performance of these drugs in clinical trials. Testing anticancer therapies in genetically engineered mouse (GEM) holds the promise of improving preclinical models and guiding the design of clinical trials. Unfortunately, the use of tumor-bearing GEM is hampered by the difficulty in simultaneously obtaining sufficient numbers of animals with the same stage of tumor development. The additional comp
APA, Harvard, Vancouver, ISO, and other styles
2

Klenner, Marbod, Pia Freidel, Mariella G. Filbin, and Alexander Beck. "DIPG-39. New preclinical models for Diffuse Midline Glioma." Neuro-Oncology 24, Supplement_1 (2022): i27. http://dx.doi.org/10.1093/neuonc/noac079.096.

Full text
Abstract:
Abstract Malignant brain tumors are the leading cause of childhood death in Germany, with Diffuse Midline Glioma (DMG) being the most lethal of all paediatric brain tumors. Current treatment strategies are limited to irradiation which prolongs survival only by a few months. Preclinical studies have identified effective drug candidates, but translation into the clinic remains a major obstacle. It is known that interactions between tumor cells and components of the TME (tumor microenvironment), such as cell to cell contacts between malignant and non-malignant cells or secreted factors, can incre
APA, Harvard, Vancouver, ISO, and other styles
3

Llaguno-Munive, Monserrat, Wilberto Villalba-Abascal, Alejandro Avilés-Salas, and Patricia Garcia-Lopez. "Near-Infrared Fluorescence Imaging in Preclinical Models of Glioblastoma." Journal of Imaging 9, no. 10 (2023): 212. http://dx.doi.org/10.3390/jimaging9100212.

Full text
Abstract:
Cancer is a public health problem requiring ongoing research to improve current treatments and discover novel therapies. More accurate imaging would facilitate such research. Near-infrared fluorescence has been developed as a non-invasive imaging technique capable of visualizing and measuring biological processes at the molecular level in living subjects. In this work, we evaluate the tumor activity in two preclinical glioblastoma models by using fluorochrome (IRDye 800CW) coupled to different molecules: tripeptide Arg-Gly-Asp (RGD), 2-amino-2-deoxy-D-glucose (2-DG), and polyethylene glycol (P
APA, Harvard, Vancouver, ISO, and other styles
4

Costa, Alice, Livia Gozzellino, Margherita Nannini, Annalisa Astolfi, Maria Abbondanza Pantaleo, and Gianandrea Pasquinelli. "Preclinical Models of Visceral Sarcomas." Biomolecules 13, no. 11 (2023): 1624. http://dx.doi.org/10.3390/biom13111624.

Full text
Abstract:
Visceral sarcomas are a rare malignant subgroup of soft tissue sarcomas (STSs). STSs, accounting for 1% of all adult tumors, are derived from mesenchymal tissues and exhibit a wide heterogeneity. Their rarity and the high number of histotypes hinder the understanding of tumor development mechanisms and negatively influence clinical outcomes and treatment approaches. Although some STSs (~20%) have identifiable genetic markers, as specific mutations or translocations, most are characterized by complex genomic profiles. Thus, identification of new therapeutic targets and development of personaliz
APA, Harvard, Vancouver, ISO, and other styles
5

Roosen, Mieke, Chris Meulenbroeks, Phylicia Stathi, et al. "BIOL-11. PRECLINICAL MODELLING OF PEDIATRIC BRAIN TUMORS USING ORGANOID TECHNOLOGY." Neuro-Oncology 25, Supplement_1 (2023): i8. http://dx.doi.org/10.1093/neuonc/noad073.030.

Full text
Abstract:
Abstract Molecular characterization has resulted in improved classification of pediatric brain tumors, leading to many novel (sub)types with distinct oncodriving events. To study tumor biology and to perform translational research on each of these tumors, preclinical models are essential. However, we are currently lacking sufficient models, especially in vitro, to represent each (sub)type and their heterogeneity. To generate large series of preclinical in vitro models for pediatric brain tumors, we are using organoid technology. Cells from patient samples and patient-derived xenograft samples
APA, Harvard, Vancouver, ISO, and other styles
6

Sewduth, Raj N., and Konstantina Georgelou. "Relevance of Carcinogen-Induced Preclinical Cancer Models." Journal of Xenobiotics 14, no. 1 (2024): 96–109. http://dx.doi.org/10.3390/jox14010006.

Full text
Abstract:
Chemical agents can cause cancer in animals by damaging their DNA, mutating their genes, and modifying their epigenetic signatures. Carcinogen-induced preclinical cancer models are useful for understanding carcinogen-induced human cancers, as they can reproduce the diversity and complexity of tumor types, as well as the interactions with the host environment. However, these models also have some drawbacks that limit their applicability and validity. For instance, some chemicals may be more effective or toxic in animals than in humans, and the tumors may differ in their genetics and phenotypes.
APA, Harvard, Vancouver, ISO, and other styles
7

Ortiz, Michael Vincent, Armaan Siddiquee, Daoqi You, et al. "Preclinical evaluation of XPO1 inhibition in Wilms tumors." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3580. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3580.

Full text
Abstract:
3580 Background: XPO1 is a nuclear export protein that selectively transports tumor and growth regulatory proteins out of the nucleus, thereby effectively inhibiting their function. We previously utilized the Virtual Inference of Protein-activity by Enriched Regulon analysis (VIPER) algorithm to discover that malignant rhabdoid tumors were dependent upon XPO1 inhibition and then evaluated a preclinical cohort using selinexor (KPT-330), the first-in-class selective inhibitor of nuclear export, to demonstrate that XPO1 inhibition was sufficient to cause cell cycle arrest, apoptosis, and disease
APA, Harvard, Vancouver, ISO, and other styles
8

Sitta, Juliana, Pier Paolo Claudio, and Candace M. Howard. "Virus-Based Immuno-Oncology Models." Biomedicines 10, no. 6 (2022): 1441. http://dx.doi.org/10.3390/biomedicines10061441.

Full text
Abstract:
Immunotherapy has been extensively explored in recent years with encouraging results in selected types of cancer. Such success aroused interest in the expansion of such indications, requiring a deep understanding of the complex role of the immune system in carcinogenesis. The definition of hot vs. cold tumors and the role of the tumor microenvironment enlightened the once obscure understanding of low response rates of solid tumors to immune check point inhibitors. Although the major scope found in the literature focuses on the T cell modulation, the innate immune system is also a promising onc
APA, Harvard, Vancouver, ISO, and other styles
9

Bella, Ángela, Claudia Augusta Di Trani, Myriam Fernández-Sendin, et al. "Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications." Cancers 13, no. 5 (2021): 963. http://dx.doi.org/10.3390/cancers13050963.

Full text
Abstract:
Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Sy
APA, Harvard, Vancouver, ISO, and other styles
10

Stripay, Jennifer L., Thomas E. Merchant, Martine F. Roussel, and Christopher L. Tinkle. "Preclinical Models of Craniospinal Irradiation for Medulloblastoma." Cancers 12, no. 1 (2020): 133. http://dx.doi.org/10.3390/cancers12010133.

Full text
Abstract:
Medulloblastoma is an embryonal tumor that shows a predilection for distant metastatic spread and leptomeningeal seeding. For most patients, optimal management of medulloblastoma includes maximum safe resection followed by adjuvant craniospinal irradiation (CSI) and chemotherapy. Although CSI is crucial in treating medulloblastoma, the realization that medulloblastoma is a heterogeneous disease comprising four distinct molecular subgroups (wingless [WNT], sonic hedgehog [SHH], Group 3 [G3], and Group 4 [G4]) with distinct clinical characteristics and prognoses has refocused efforts to better d
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Preclinical tumor models"

1

MINOLI, LUCIA. "TUMOR MICROENVIRONMENT IN EXPERIMENTAL PRECLINICAL MOUSE MODELS OF HUMAN CANCER: MORPHOLOGICAL APPROACH." Doctoral thesis, Università degli Studi di Milano, 2020. http://hdl.handle.net/2434/704551.

Full text
Abstract:
One of the recent advancements in oncological research has been the recognition of the tumor microenvironment (TME) as a relevant participant during all stages of the evolution of a neoplastic process. Indeed, over the past decades, tumors have been considered through a changing perspective: no longer as a growth of homogeneous neoplastic cells, but as an actual organ composed of different cell populations and structures: the parenchyma being the neoplastic population and the stroma, including the vascular network and infiltrating cells. The tumor microenvironment has a dual role in tumor biol
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Liu Qi. "Development and Application of AcidoCEST MRI for Evaluating Tumor Acidosis in Pre-Clinical Cancer Models." Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/323450.

Full text
Abstract:
Tumor acidosis is an important biomarker in cancer. We have developed a noninvasive imaging method, termed acidosis Chemical Exchange Saturation Transfer (acidoCEST) MRI to measure extracellular pH (pHe) in the tumor microenvironment. Chapter 1 introduces the importance of measuring tumor acidosis and presents various imaging modalities and their shortcoming to measure pHe. Chapter 2 describes the optimization of acidoCEST MRI for in vivo pHe measurement. The acidoCEST MRI protocol consists of a CEST-FISP acquisition and Lorentzian line shape fittings. We determined the optimal saturation time
APA, Harvard, Vancouver, ISO, and other styles
3

Denton, Nicholas Lee Denton. "Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1523892800897524.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

TOSCA, ELENA MARIA. "Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings." Doctoral thesis, Università degli studi di Pavia, 2019. http://hdl.handle.net/11571/1242427.

Full text
Abstract:
Il processo di sviluppo di un nuovo farmaco oncologico e' caratterizzato da un elevatissimo numero di fallimenti, principalmente dovuti alla scarsa efficacia o eccessiva tossicita' riscontrata durante le fasi di sperimentazione clinica. Tra le possibili cause di questo fenomeno vi sono l'utilizzo di modelli animali poco rappresentativi della condizione umana e la mancanza di un paradigma di traslazione dal contesto preclinico a quello clinico sufficientemente predittivo. L'utilizzo di modelli farmacometrici, capaci di estrapolare, sintetizzare e integrare le informazioni raccolte durante la sp
APA, Harvard, Vancouver, ISO, and other styles
5

Lahr, Christoph Alexander. "Tissue-engineering humanised bone sarcoma models in rodents-a preclinical study platform for orthopaedic research." Thesis, Queensland University of Technology, 2021. https://eprints.qut.edu.au/207759/1/Christoph%20Alexander_Lahr_Thesis.pdf.

Full text
Abstract:
This thesis is a step forward in preclinical in-vivo disease modelling, designed to find new diagnostic and therapeutic options, to ultimately improve the poor outcome of patients with primary bone cancer. Combining the principles of tissue-engineering, 3D-printing and advanced gene editing techniques the preclinical animal models developed in this thesis have important clinical implications that could shape future innovative treatment plans. Particularly the translation of a humanised osteosarcoma model from a mouse into a newly engineered severely immunocompromised rat will facilitate precli
APA, Harvard, Vancouver, ISO, and other styles
6

Laranga, Roberta <1985&gt. "Development of Preclinical Models of Mammary Carcinogenesis: Functional Role of Her2 and its Isoforms in Tumor Progression and in Drug Resistance." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2017. http://amsdottorato.unibo.it/7832/1/Laranga_Roberta_Tesi.pdf.

Full text
Abstract:
Overexpression of huHER2 occurs in nearly 15–20% of breast cancers, and it is generally associated with poor patient survival. Existing therapies such as trastuzumab and lapatinib are currently used in the treatment of HER2-positive cancers, although issues with high recurrence and acquired resistance still remain. Elucidation of the molecular mechanisms underlying resistance is leading to the identification of therapies and strategies to manage resistance to HER2-targeted therapies. In addition to intrinsic and acquired resistance associated to HER2 oncogene, the induction of bypass pathways
APA, Harvard, Vancouver, ISO, and other styles
7

Fuchs, Jeannette [Verfasser], and Thorsten [Akademischer Betreuer] Stiewe. "Establishment and characterization of preclinical mouse models for evaluation of oncogenic and tumor-suppressive properties of p53 family members / Jeannette Fuchs ; Betreuer: Thorsten Stiewe." Marburg : Philipps-Universität Marburg, 2017. http://d-nb.info/1131253272/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ferreira, Luís Pedro Correia Pinto. "Development of multicelular 3D cancer testing platforms for evaluation of new anti-cancer therapies." Master's thesis, Universidade de Aveiro, 2017. http://hdl.handle.net/10773/22713.

Full text
Abstract:
Mestrado em Bioquímica Clínica<br>O cancro do pulmão (CP) é um dos cancros mais diagnosticados a nível mundial e também um dos mais mortíferos. Atualmente, as terapias administradas a nível clínico para o tratamento do CP são ainda extremamente ineficazes e limitadas no que diz respeito ao aumento da taxa de sobrevivência dos pacientes oncológicos. Esta realidade demonstra a necessidade de investigar ativamente novas terapias para o tratamento desta neoplasia. No entanto a validação pré-clínica de terapias inovadoras para o CP tem-se revelado extremamente difícil devido à inexistência de plat
APA, Harvard, Vancouver, ISO, and other styles
9

Wolska-Krawczyk, Malgorzata [Verfasser], and Arno [Akademischer Betreuer] Bücker. "Evaluation of liver tumor perfusion by intraarterial transcatheder magnetic resonance angiography during transarterial chemoembolization in patients with hepatocellular carcinoma : Preclinical instrument validation in vascular models and clinical study / Malgorzata Wolska-Krawczyk. Betreuer: Arno Bücker." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2014. http://d-nb.info/1056906979/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dobosz, Michael [Verfasser], Vasilis [Akademischer Betreuer] Ntziachristos, and Hans-Jürgen [Akademischer Betreuer] Wester. "The application of in vivo and ex vivo multispectral epi-fluorescence imaging for the preclinical discovery and development of monoclonal antibodies in tumor xenograft models / Michael Dobosz. Betreuer: Vasilis Ntziachristos. Gutachter: Hans-Jürgen Wester ; Vasilis Ntziachristos." München : Universitätsbibliothek der TU München, 2014. http://d-nb.info/1080903682/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Preclinical tumor models"

1

Fiebig, H. H. Revelance Of Tumor Models For Anticancer Drug Development (CONTRIBUTIONS TO ONCOLOGY). Edited by H. H. Fiebig. Karger, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Powell, Craig M. PTEN and Autism With Macrocepaly. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199744312.003.0010.

Full text
Abstract:
Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN) is a gene encoding an intracellular signaling molecule. PTEN was originally discovered as the gene responsible for a subset of familial hamartoma (tumor) syndromes associated with increased risk for certain cancers (Nelen et al., 1997) and as a gene often mutated in human cancers and tumor cell lines (Li et al., 1997; Steck et al., 1997). More recently, mutations in PTEN have been linked genetically to the clinical phenotype of autism or developmental delay with macrocephaly (Boccone et al., 2006; Butler et al., 2005; Buxbaum et al
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Preclinical tumor models"

1

Teicher, Beverly A. "Preclinical Tumor Response End Points." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morton, Christopher L., and Peter J. Houghton. "The Pediatric Preclinical Testing Program." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gerner, Eugene W., Natalia A. Ignatenko, and David G. Besselsen. "Preclinical Models for Chemoprevention of Colon Cancer." In Tumor Prevention and Genetics. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55647-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Boss, Mary-Keara, Gregory M. Palmer, and Mark W. Dewhirst. "Imaging the Hypoxic Tumor Microenvironment in Preclinical Models." In Hypoxia and Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9167-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nathanson, S. David. "Preclinical Models of Regional Lymph Node Tumor Metastasis." In Cancer Metastasis And The Lymphovascular System: Basis For Rational Therapy. Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-69219-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hillman, Gilda G. "Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approaches." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sadekar, Shraddha, Isabel Figueroa, and Harish Shankaran. "Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models: A Quantitative Approach." In Development of Antibody-Based Therapeutics. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0496-5_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Parchment, Ralph E. "Bone Marrow as a Critical Normal Tissue that Limits Drug Dose/Exposure in Preclinical Models and the Clinic." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chambers, Ann F., Eva A. Turley, John Lewis, and Leonard G. Luyt. "Preclinical Cell and Tumor Models for Evaluating Radiopharmaceuticals in Oncology." In Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470613214.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jacoberger-Foissac, Celia, Bertrand Allard, David Allard, and John Stagg. "Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models." In Methods in Molecular Biology. Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2914-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Preclinical tumor models"

1

Joachim, Anais, Marielle Mello, Emilie Maturin, et al. "879 Deep immunoprofiling of tumor mouse models for preclinical studies." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0879.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bagley, Rebecca G., Yi Ren, Leslie Kurtzberg, William Weber, Dinesh Bangari, and Beverly A. Teicher. "Abstract 1596: Human choriocarcinomas: Placental growth factor-dependent preclinical tumor models." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Faia, Kerrie, Alberto Toso, Kristina Fetalvero, et al. "Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Welm, Alana L. "Abstract IA07: Breast tumor grafts as preclinical models for anti-metastasis therapy." In Abstracts: AACR Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications - October 3-6, 2013; San Diego, CA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1557-3125.advbc-ia07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Doody, Jacqueline, Sneha Mathew, Lan Wu, et al. "Abstract 3539: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3539.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Li, Yanxia, Sneha Mathew, Lan Wu, et al. "Abstract C224: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c224.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Yanxia, Sneha Mathew, Lan Wu, et al. "Abstract A235: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Staniszewska, Anna, Joshua Armenia, Matthew King, et al. "Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Heuer, Timothy S., Richard Ventura, Joanna Waszczuk, et al. "Abstract 1815: Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sriram, Venkataraman, Michael E. Bigler, Holly Cherwinski, Erin Murphy, Terrill K. McClanahan, and Joseph H. Phillips. "Abstract 5025: Dissecting the dynamics of anti-PD1 immunotherapy in preclinical tumor models." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-5025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Preclinical tumor models' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography